Preserved Serial Echocardiographic Function Despite Cardiovascular Events During Fluoropyrimidine-Based Chemotherapy

Background: Treatment of gastrointestinal cancers usually requires a combination of different chemotherapeutic drugs, predominantly fluoropyrimidines, which may result in cardiotoxicity. The main aim of the study was to assess the impact of chemotherapy on left ventricular function assessed in echocardiography. Methods: The single-center study included 63 patients [mean age of 66.4 (9.9) years, male (52.4%)], diagnosed with gastrointestinal cancer (colorectal cancer: n = 51, 81%). The most common chemotherapy regimen was FOLFOX 4 (oxaliplatin, 5-fluorouracil, levofolinic acid). Patients underwent echocardiography before the first cycle of chemotherapy and after a follow-up period of 6 months. In addition to standard echocardiographic parameters, left ventricular ejection fraction (LVEF) was measured using the 3D method and myocardial strain analysis was performed using the speckle-tracking technique (global longitudinal strain—GLS). Results: The mean LVEF of the study group was 58.9 (5.7)% and mean GLS was −17.2 (3.6)%. After the follow-up period, no statistically significant changes in LVEF, GLS, or diastolic function parameters were observed, irrespective of cancer type and chemotherapeutic drug. During follow-up, seven patients (11.1%) died due to the progression of cancer. Symptoms of possible fluoropyrimidine-induced cardiotoxicity (FIC) were observed in five cases, with cardiac arrhythmias being the most frequent manifestation (premature ventricular complexes, atrial fibrillation, and atrioventricular blocks). Conclusions: In this single-center study we showed that fluoropyrimidine-based chemotherapy was not associated with significant short-term deterioration in serial echocardiographic indices of LV systolic or diastolic function. However, clinically relevant cardiovascular events still occurred, underscoring that preserved LVEF and GLS do not exclude fluoropyrimidine-associated cardiovascular toxicity.

Authors

Institutions

Publication Details

Journal
Journal of Clinical Medicine
Published
2026-11-12
DOI
https://doi.org/10.3390/jcm15228837
Primary Topic
Chemotherapy-induced cardiotoxicity and mitigation
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Preserved Serial Echocardiographic Function Despite Cardiovascular Events During Fluoropyrimidine-Based Chemotherapy

Karol Adam Kamiński, Ewelina Kazimierczyk, Małgorzata Knapp, Remigiusz Kazimierczyk et al.
Journal of Clinical Medicine
Chemotherapy-induced cardiotoxicity and mitigation
article

Preserved Serial Echocardiographic Function Despite Cardiovascular Events During Fluoropyrimidine-Based Chemotherapy

Karol Adam Kamiński, Ewelina Kazimierczyk, Małgorzata Knapp, Remigiusz Kazimierczyk, Mariola Kucharewicz, Anna Lisowska
article en

Abstract

Background: Treatment of gastrointestinal cancers usually requires a combination of different chemotherapeutic drugs, predominantly fluoropyrimidines, which may result in cardiotoxicity. The main aim of the study was to assess the impact of chemotherapy on left ventricular function assessed in echocardiography. Methods: The single-center study included 63 patients [mean age of 66.4 (9.9) years, male (52.4%)], diagnosed with gastrointestinal cancer (colorectal cancer: n = 51, 81%). The most common chemotherapy regimen was FOLFOX 4 (oxaliplatin, 5-fluorouracil, levofolinic acid). Patients underwent echocardiography before the first cycle of chemotherapy and after a follow-up period of 6 months. In addition to standard echocardiographic parameters, left ventricular ejection fraction (LVEF) was measured using the 3D method and myocardial strain analysis was performed using the speckle-tracking technique (global longitudinal strain—GLS). Results: The mean LVEF of the study group was 58.9 (5.7)% and mean GLS was −17.2 (3.6)%. After the follow-up period, no statistically significant changes in LVEF, GLS, or diastolic function parameters were observed, irrespective of cancer type and chemotherapeutic drug. During follow-up, seven patients (11.1%) died due to the progression of cancer. Symptoms of possible fluoropyrimidine-induced cardiotoxicity (FIC) were observed in five cases, with cardiac arrhythmias being the most frequent manifestation (premature ventricular complexes, atrial fibrillation, and atrioventricular blocks). Conclusions: In this single-center study we showed that fluoropyrimidine-based chemotherapy was not associated with significant short-term deterioration in serial echocardiographic indices of LV systolic or diastolic function. However, clinically relevant cardiovascular events still occurred, underscoring that preserved LVEF and GLS do not exclude fluoropyrimidine-associated cardiovascular toxicity.

Journal of Clinical MedicineVol. 15(22)
Medical University of Białystok (PL)
Good health and well-being
Chemotherapy-induced cardiotoxicity and mitigation
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon